ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

LPCN Lipocine Inc

4.7983
0.2483 (5.46%)
26 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Lipocine Inc LPCN NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.2483 5.46% 4.7983 23:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
4.52 4.38 4.8099 4.7977 4.55
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
11/4/202406:00PRNUSLipocine Announces Positive LPCN 2401 Clinical Results..
28/3/202407:00PRNUSLipocine Announces Positive Week 52 Results from LPCN 1148..
25/3/202407:00PRNUSLipocine Announces First Cohort Dosed in Pivotal Study of..
07/3/202416:31EDGAR2Form 8-K - Current report
07/3/202407:00PRNUSLipocine Announces Financial Results for the Full Year Ended..
07/3/202405:08EDGAR2Form 8-K - Current report
07/3/202405:07EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
06/3/202407:00PRNUSLipocine to Present at 36th Annual Roth Conference
06/3/202405:01EDGAR2Form 8-K - Current report
12/2/202415:10EDGAR2Form 8-K - Current report
06/2/202407:00PRNUSLipocine Announces Confirmation of Dosing Regimen for..
02/2/202407:00PRNUSLipocine Announces Continued Commercialization of TLANDO®..
18/1/202407:20EDGAR2Form 8-K - Current report
18/1/202407:00PRNUSLipocine and Verity Pharma Enter into License Agreement for..
19/12/202309:00EDGAR2Form 8-K - Current report
19/12/202307:00PRNUSLipocine to Present at Biotech Showcase 2024
22/11/202315:15EDGAR2Form S-3 - Registration statement under Securities Act of..
13/11/202313:45EDGAR2Form 8-K - Current report
13/11/202313:45PRNUSLipocine Releases Late Breaking Presentation on LPCN 1148..
08/11/202312:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202308:50EDGAR2Form 8-K - Current report
08/11/202307:00PRNUSLipocine Announces Financial Results for the Third Quarter..
01/11/202308:31EDGAR2Form 8-K - Current report
01/11/202307:00PRNUSLipocine to Present Clinical Data on LPCN 1148 at The Liver..
26/10/202308:35EDGAR2Form 8-K - Current report
26/10/202307:00PRNUSLipocine Completes Successful Meeting with FDA on LPCN 1154..
23/10/202318:00PRNUSLipocine to Present at the H.C. Wainwright Annual NASH..
06/10/202315:05EDGAR2Form 8-K - Current report
19/9/202315:10EDGAR2Form 8-K - Current report
19/9/202315:05PRNUSLipocine to Present at the Cantor Fitzgerald Global..
10/8/202307:35EDGAR2Form 8-K - Current report
10/8/202307:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202307:00PRNUSLipocine Announces Financial Results for the Second Quarter..
27/7/202305:45EDGAR2Form 8-K - Current report
27/7/202305:30PRNUSLPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients..
14/6/202307:00PRNUSLipocine to Present at H.C. Wainwright Annual..
07/6/202307:00PRNUSLipocine to Present LPCN 1148 and LPCN 1144 at the EASL..
16/5/202306:00PRNUSPositive Topline Clinical Results Support Streamlined..
11/5/202305:00PRNUSLipocine Announces Financial Results for the First Quarter..

Su Consulta Reciente

Delayed Upgrade Clock